Further preclinical research, clinical trials, and discussions will be necessary to address the issues of specific tumor types most responsive to VISTA blockade, the effects of prior therapies, and potential biomarkers most predictive of clinical response, all of which are likely to substantially impact the beneficial effects of VISTA blockade in cancer patients. This evidence concerns the gene VSIR and cancer.